Terms: = Prostate cancer AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Diagnosis
6741 results:
1. Clinical utility of [68Ga]Ga-PSMA-11 PET/CT in initial staging of patients with prostate cancer and importance of intraprostatic SUVmax values.
Rogic I; Golubic AT; Zuvic M; Smitran T; Jukic N; Gamulin M; Kastelan Z; Huic D
Nucl Med Rev Cent East Eur; 2024; 27(0):6-12. PubMed ID: 38680016
[TBL] [Abstract] [Full Text] [Related]
2. A population-based propensity score matching analysis of risk factors and the impact on survival associated with refusal of cancer-directed surgery in patients with prostate cancer.
Tang Y; Gao Y; Zhang R; Li T; Yang Y; Huang L; Wei Y
Sci Rep; 2024 Apr; 14(1):9494. PubMed ID: 38664545
[TBL] [Abstract] [Full Text] [Related]
3. [Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].
Jin Y; Zhai ZW; Sun LT; Xia PD; Hu H; Jiang CQ; Zhao BC; Qu H; Qian Q; Dai Y; Yao HW; Wang ZJ; Han JG
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):403-411. PubMed ID: 38644246
[No Abstract] [Full Text] [Related]
4. Patterns of Care for Medicare Beneficiaries With Metastatic prostate cancer.
Filson CP; Richards TB; Ekwueme DU; Howard DH
Urol Pract; 2024 May; 11(3):489-497. PubMed ID: 38640419
[TBL] [Abstract] [Full Text] [Related]
5. Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized prostate cancer.
Basourakos SP; An A; Davuluri M; Pinheiro LC; Al Awamlh BAH; Borregales LD; Luan D; Tamimi RM; Hu JC; Kensler KH
Urol Pract; 2024 May; 11(3):538-546. PubMed ID: 38640417
[TBL] [Abstract] [Full Text] [Related]
6. [Study on the length and quality of prostate biopsy tissue strips].
Geng YS; Gao YQ; Cao FH; Wu S; Ding XF
Zhonghua Nan Ke Xue; 2023 Dec; 29(12):1000-1005. PubMed ID: 38639952
[TBL] [Abstract] [Full Text] [Related]
7. [Influence factors of erectile dysfunction in patients with localized prostate cancer after radical surgery].
Wang SH; Shi XQ; Ma MF; Jin XX; Zhao XD; Zhou YL; Gu YF; Hu J; Dong N; Dong J; Xu S
Zhonghua Nan Ke Xue; 2023 Dec; 29(12):992-999. PubMed ID: 38639951
[TBL] [Abstract] [Full Text] [Related]
8. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients].
Wu D; Yi XM; Wei HX; Zhang KX; Shi CJ; Shi XQ; Xu ZY; Fu D
Zhonghua Nan Ke Xue; 2023 Sep; 29(9):831-836. PubMed ID: 38639597
[TBL] [Abstract] [Full Text] [Related]
9. Relevance of blood tumor markers in inpatients with significant involuntary weight loss and elevated levels of inflammation biomarkers.
Gronnier M; Hedhli K; Sauzay C; Salle V; Duhaut P; Schmidt J; Dernoncourt A
BMC Cancer; 2024 Apr; 24(1):468. PubMed ID: 38622530
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical study of artificial intelligence-guided image fusion assisted transperineal prostate biopsy].
Hu J; Zhao XD; Zhou YL; Dong N; Ma MF; Chen YH; Sheng ZC; Dong J; He CQ; Xu S
Zhonghua Nan Ke Xue; 2023 Aug; 29(8):729-735. PubMed ID: 38619521
[TBL] [Abstract] [Full Text] [Related]
11. [A single center study:An analysis of the safety and validity of delaying repeated biopsy for patients with atypical small acinar proliferation].
Ji WT; Liu DC; Cui WL; Hu Y; Wang Y; Tan JF
Zhonghua Nan Ke Xue; 2023 May; 29(5):414-419. PubMed ID: 38602757
[TBL] [Abstract] [Full Text] [Related]
12. Is Unilateral Lymphadenectomy an Option in Selected Patients with prostate cancer?
Kassab BN; De Pablos-Rodríguez P; Ferrer ÁG; García AC; Fons AC; Aragón F; Ramón-Borja JC; Ramírez-Backhaus M
Arch Esp Urol; 2024 Mar; 77(2):129-134. PubMed ID: 38583004
[TBL] [Abstract] [Full Text] [Related]
13. The trend of dental check-up and prevalence of dental complications following the use of bone modifying agents in patients with metastatic breast and prostate cancer: analysis of data from the Korean National Health Insurance Service.
Lim AR; Park W; Moon SJ; Kim MS; Lee S
BMC Health Serv Res; 2024 Apr; 24(1):412. PubMed ID: 38566103
[TBL] [Abstract] [Full Text] [Related]
14. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract] [Full Text] [Related]
15. Role of body mass index and weight change in the risk of cancer: A systematic review and meta-analysis of 66 cohort studies.
Shi X; Deng G; Wen H; Lin A; Wang H; Zhu L; Mou W; Liu Z; Li X; Zhang J; Cheng Q; Luo P
J Glob Health; 2024 Mar; 14():04067. PubMed ID: 38547495
[TBL] [Abstract] [Full Text] [Related]
16. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
[TBL] [Abstract] [Full Text] [Related]
17. Machine-learning Algorithm-based Risk Prediction and Screening-detected prostate cancer in A Benign prostate Hyperplasia Cohort.
Chang CC; Chiou JK; Lin CJ; Lu K; Li JR; Chang LW; Hung SC; Cheng CL
Anticancer Res; 2024 Apr; 44(4):1683-1693. PubMed ID: 38537959
[TBL] [Abstract] [Full Text] [Related]
18. Paraneoplastic Syndromes in Neuroendocrine prostate cancer: A Systematic Review.
Abufaraj M; Ramadan R; Alkhatib A
Curr Oncol; 2024 Mar; 31(3):1618-1632. PubMed ID: 38534956
[TBL] [Abstract] [Full Text] [Related]
19. [Chinese expert consensus on the follow-up management of patients with prostate cancer receiving medical castration therapy(2024 edition)].
Chinese Prostate Cancer Consortium
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(0):285-295. PubMed ID: 38527740
[TBL] [Abstract] [Full Text] [Related]
20. Contemporary Diagnostic Reporting for Prostatic Adenocarcinoma: Morphologic Aspects, Molecular Correlates, and Management Perspectives.
Muthusamy S; Smith SC
Adv Anat Pathol; 2024 May; 31(3):188-201. PubMed ID: 38525660
[TBL] [Abstract] [Full Text] [Related]
[Next]